[Skip to the chapter](#reading)

[Selank](/)
A plain guide to care

Open the chapter index

Begin

[Start here](/)
[Selank](/primer/)
[Peptide](/peptide-primer/)

Understand the words

[Approval](/approval-primer/)
[Compounding](/compounding-primer/)
[Withdrawn request](/withdrawn-primer/)
[Placebo](/placebo-primer/)

Read the findings

[Human evidence](/source-primer/)
[Memory claims](/memory-primer/)
[Unknown harm](/safety-primer/)
[Interaction](/interaction-primer/)
[Listed exclusions](/careful-with/)

Prepare for care

[Telehealth](/telehealth-primer/)
[Licence](/licence-primer/)
[Questions to ask](/primer-questions/)
[Cost](/cost-primer/)
[Insurance words](/insurance-primer/)
[A plain next step](/plain-start/)

A plain-language guide / Unknown harm

# What is known about harm?

A short list of reported problems is not a full answer.

Large studies and long studies have not settled how much harm Selank may cause.

FDA says important information about harm in people is missing.

## What the maker lists

The maker’s Russian leaflet lists an unpleasant taste and possible allergic reactions.

An allergy is a reaction to a substance.

The leaflet does not say how many people had these problems.

A brief list does not prove that other problems cannot occur.

## What FDA is concerned about

FDA warns about a possible immune reaction to Selank.

An immune reaction means the body may treat the substance as an invader.

The warning refers to some ways of giving Selank without naming them. It does not say whether it means nose drops, injections, or both.

FDA is concerned that clumps of Selank or unwanted material mixed with it could trigger that reaction. This warning does not prove that a particular product contains unwanted material.

## If a medicine causes a problem

Patients can report suspected medicine problems through MedWatch, FDA’s free reporting service.

A report records what happened, without proving that the medicine was the cause.

[Find FDA’s MedWatch service](https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program) ↗

[Read about medicine interactions](/interaction-primer/) ↗

## Notes for this chapter

[FDA: Selank’s concern entry](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)

FDA’s page says its content was current on April 22, 2026. The safety information was checked on September 30, 2026.

The maker’s Russian leaflet

It lists taste and allergy problems, but does not give a full account of possible harm.

[PubMed: a clinical review](https://pubmed.ncbi.nlm.nih.gov/34396551/)

The review describes the limited research.

[FDA: limits of problem reports](https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/fda-adverse-event-monitoring-system-aems-public-dashboard)

A report and a proven cause are different things.

Previous — [← Memory claims](/memory-primer/)

Continue — [Interaction →](/interaction-primer/)

This guide helps you make sense of Selank care; it does not treat patients or sell treatment.

[Back to start](/)

[Plain text of this chapter](/safety-primer/index.md)